Drug discovery
Work with us to identify and advance novel approaches with the potential to deliver the next generation of cancer medicines.
The STRIDE(a) study will determine if Stimuvax can extend progression-free survival in patients treated with hormonal therapy who have hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer.
Stimuvax® is a liposomal peptide vaccine against the tumour-associated protein MUC1. The vaccine was developed by Oncothyreon (formerly Biomira) under a portfolio of patents licensed by CRT, following Cancer Research UK-funded investigations led by Prof Joyce Taylor-Papadimitriou at Guy’s Hospital, London. Stimuvax was the first investigational cancer vaccine to enter Phase III clinical testing in NSCLC with the February 2007 launch of the STARTb study, which will involve more than 1,300 patients with unresectable stage III NSCLC, who were stable or responding after chemoradiotherapy.
